vs
Side-by-side financial comparison of Ellington Credit Co (EARN) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.
Prelude Therapeutics Inc is the larger business by last-quarter revenue ($6.5M vs $6.1M, roughly 1.1× Ellington Credit Co). Ellington Credit Co runs the higher net margin — -32.6% vs -303.5%, a 270.8% gap on every dollar of revenue. On growth, Ellington Credit Co posted the faster year-over-year revenue change (1528.9% vs 116.7%).
Ellington Management Group is an American hedge fund firm. As of June 2019, the firm was reportedly managing $8.5 billion in structured products and other credit instruments.
EARN vs PRLD — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.1M | $6.5M |
| Net Profit | $-2.0M | $-19.7M |
| Gross Margin | — | — |
| Operating Margin | -35.6% | -314.1% |
| Net Margin | -32.6% | -303.5% |
| Revenue YoY | 1528.9% | 116.7% |
| Net Profit YoY | -116.1% | 38.9% |
| EPS (diluted) | — | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $6.5M | ||
| Q4 24 | $6.1M | — | ||
| Q3 24 | $4.8M | $3.0M | ||
| Q2 24 | $3.9M | — | ||
| Q1 23 | $-372.0K | — | ||
| Q4 22 | $2.5M | — | ||
| Q3 22 | $5.2M | — | ||
| Q2 22 | $7.1M | — |
| Q3 25 | — | $-19.7M | ||
| Q4 24 | $-2.0M | — | ||
| Q3 24 | $5.4M | $-32.3M | ||
| Q2 24 | $-815.0K | — | ||
| Q1 23 | $2.3M | — | ||
| Q4 22 | $11.7M | — | ||
| Q3 22 | $-13.7M | — | ||
| Q2 22 | $-10.7M | — |
| Q3 25 | — | -314.1% | ||
| Q4 24 | -35.6% | — | ||
| Q3 24 | — | -1145.9% | ||
| Q2 24 | -22.8% | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | — | -303.5% | ||
| Q4 24 | -32.6% | — | ||
| Q3 24 | 114.6% | -1075.7% | ||
| Q2 24 | -20.9% | — | ||
| Q1 23 | -628.2% | — | ||
| Q4 22 | 476.7% | — | ||
| Q3 22 | -263.5% | — | ||
| Q2 22 | -150.9% | — |
| Q3 25 | — | $-0.26 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.43 | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.8M | $55.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $193.7M | $58.5M |
| Total Assets | $824.1M | $94.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $55.0M | ||
| Q4 24 | $31.8M | — | ||
| Q3 24 | $25.7M | $153.6M | ||
| Q2 24 | $118.8M | — | ||
| Q1 23 | $36.7M | — | ||
| Q4 22 | $34.8M | — | ||
| Q3 22 | $25.4M | — | ||
| Q2 22 | $37.5M | — |
| Q3 25 | — | $58.5M | ||
| Q4 24 | $193.7M | — | ||
| Q3 24 | $191.6M | $156.4M | ||
| Q2 24 | $146.1M | — | ||
| Q1 23 | $115.0M | — | ||
| Q4 22 | $112.4M | — | ||
| Q3 22 | $103.0M | — | ||
| Q2 22 | $118.6M | — |
| Q3 25 | — | $94.8M | ||
| Q4 24 | $824.1M | — | ||
| Q3 24 | $752.3M | $197.2M | ||
| Q2 24 | $933.5M | — | ||
| Q1 23 | $1.1B | — | ||
| Q4 22 | $1.1B | — | ||
| Q3 22 | $1.2B | — | ||
| Q2 22 | $1.1B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.4M | $-19.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-19.1M | ||
| Q4 24 | $4.4M | — | ||
| Q3 24 | $3.2M | $-27.3M | ||
| Q2 24 | $2.7M | — | ||
| Q1 23 | $-2.4M | — | ||
| Q4 22 | $4.2M | — | ||
| Q3 22 | $4.2M | — | ||
| Q2 22 | $7.1M | — |
| Q3 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-27.4M | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -912.0% | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | — | 0.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | — | — | ||
| Q1 23 | -1.02× | — | ||
| Q4 22 | 0.36× | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
